The aim of this randomised controlled study was to compare continuous subcutaneous insulin infusion using an insulin pump with the traditional continuous intravenous infusion method for tight glycaemic control. Sixty patients admitted to our University Hospital medical intensive care unit with an initial blood glucose level over 6.1 mmol/l, were enrolled and randomised into two treatment groups: the subcutaneous insulin group received continuous subcutaneous insulin infusion and the intravenous group received insulin by traditional intravenous infusion with infusers. Three patients died in the first 24 hours and were excluded from the final analysis. Insulin therapy was administered to both groups according to the previously designed and used protocol in the department. The target glucose level was 4.4 to 6.1 mmol/l. There was no significant difference in mortality between the groups. However mean blood glucose level was found to be lower (6.56±0.82 mmol/l vs. 7.85±1.6 mmol/l, P=0.00055) in the subcutaneous insulin group. According to Vogelzang's hyperglycaemic index, better glycaemic control was achieved in the subcutaneous insulin group while there was no significant difference in terms of hypoglycaemic events. Daily insulin bolus and infusion requirements were also significantly lower in the subcutaneous insulin group. Despite the small number of patients involved in this study in a medical intensive care unit, strict blood glucose control using a subcutaneous insulin pump was achieved more efficiently than the traditional intravenous infusion method without increasing hypoglycaemic events.
Hyperglycaemia is a frequent metabolic disorder encountered in critically ill patients. Even in nondiabetic patients with life-threatening pathologies such as sepsis, trauma, burns, acute pancreatitis, cerebrovascular disorders or myocardial infarction, hyperglycaemia occurs and should be treated. Until the publication of the study of Van den Berghe et al demonstrating a notable improvement in in-hospital mortality and morbidity among surgical intensive care patients 1 , hyperglycaemia in the intensive care unit (ICU) was treated with the same target glycaemic levels as in insulin-dependent diabetic outpatients. After this study, glycaemia and its proposed adverse effects on cell functions in critical illness became a growing point of interest among researchers. The effect of hyperglycaemia in compromising immune function, on systemic mitochondrial ultrastructure and function is now better understood [2] [3] [4] [5] . Despite the success of tight glycaemic control in reducing mortality among surgical ICU patients, this procedure had an inverse impact in patients staying less than three days in the medical ICU 6 (MICU). Hypoglycaemic episodes were considered as the possible cause since risk factor for death.
One of the ways to reduce hypoglycaemic events is probably through a safer blood glucose control protocol that can be achieved by changing the target blood glucose levels or by increasing the frequency of blood glucose measurements. An alternative way may also be the change in the route of insulin administration. As continuous intravenous (IV) insulin administration is considered the most other routes of continuous infusion have not been advocated. Continuous subcutaneous insulin infusion (CSII) is a well known and successful method used in type 1 diabetic patients 7, 8 . This procedure is accomplished with a portable insulin cannula placed under the skin of the patient. The pump allows the delivery of continuous basal insulin but also bolus doses if needed such as with food intake or correction doses for hyperglycaemia. These complex features and the cost of the pumps limit the widespread use of these devices.
We hypothesised that CSII could be safer than intravenous infusion because its more delayed action permits early awareness of an eventual trend toward hypoglycaemia. The aim of this randomised study compared to IV insulin infusion for tight glycaemic control using the same treatment and measurement as the ability to reduce hyperglycaemia and the
MATERIAL AND METHOD

Study population
Patients admitted to our six-bed University Hospital MICU between October 2006 and February 2007 with admission glycaemia over 6.1 mmol/l were randomised into two groups; subcutaneous insulin (SI) and intravenous (IV) group, using randomisation software. Blood samples were obtained for baseline biochemistry, blood gases and glycaemia within 30 minutes of admission to the ICU. The exclusion criteria were age less than 18, end-stage malignancy, suspicion of brain death and refusal to sign informed consent form by the patient or the closest family member. The study started after approval by the Ethical Committee for Clinical Research of the University.
Study design
The targeted blood sugar level for glycaemic Leuven study 6 . Glycaemia less than 2.2 mmol/l was considered as hypoglycaemia and values between measurement interval was adjusted according to the protocol already in use in the MICU for more than six months and all measurements were performed by the attending physician or the attending intern physicians and one intern at any time in the MICU, each physician attending for three patients and the intern for six patients. The physicians are fellows in internal medicine and accomplish a three-month rotation in intensive care while the intern is changed each month. At their arrival, they were all briefed about the study and received training in the use of the glucose meters as well as the protocols in use in the ICU by the ICU director and a senior nurse.
Glucose measurements
Homemade software was used to guide the timing of blood sugar measurements in order to minimise non-adherence to the protocol. The software was designed to emit an alarm sound for the measurement time. This was effective as no measurements were missed.
Blood glucose measurements were conducted on mainly arterial and less frequently on capillary blood samples using two identical bedside glucometers photometry (Accu-Chek Advantage, F. Hoffmann-La Roche Ltd, Basel, Switzerland). Glucometers are cleaned and calibrated by a senior nurse every Monday according to ICU protocol.
Nutrition
All haemodynamically stable patients received enteral feeding solutions (Jevity Plus, Abbott Laboratories, USA) with an energy content of 20 to 30 kcal/kg if possible. Patients unable to tolerate enteral feeding received balanced total parenteral nutrition (TPN; Oliclinomel N7-1000E, Baxter International Inc, USA) of equal energy amount. Enteral feeding was resumed as soon as possible. A rather aggressive nutrition policy is adopted in the MICU (Figure 1 ). Mean calorie intake per body is reported. Days in ICU Calorie Intake (Kcal/kg per day) 
Insulin preparation and infusion
For applicability of our results in daily clinical practice, our standard protocol for insulin dosing and blood glucose measurement interval was used in both groups (Table 1 ). In the IV group, insulin was infused by perfusors (Perfusor FM pump, B. Braun, Germany) using a 60 ml syringe containing 50 IU regular insulin (Humulin R, Eli Lilly, USA) concentration of 1 IU/ml. The SI group received insulin via the original tube and cannula of the insulin pump (Deltec Cozmo, Smiths-Medical, USA). The cannula was placed subcutaneously in the abdominal region or thighs. The cannulation site was changed every three days or when the cartridge of the pump was empty as recommended by the manufacturer. The cartridge of insulin pumps contained 3 ml (100 IU/ml) of undiluted regular insulin.
Data collection
The demographic and clinical features of patients were recorded upon admission and are summarised in Table 2 . Acute Physiology and Chronic Health each patient. The complete blood count, routine biochemistry and serum C-reactive protein levels were followed on a daily basis.
Endpoints
The primary endpoints were the rate of in-range glycaemic measurements, the time required to lower the glycaemia between target levels and the number of hypoglycaemic events. Secondary endpoints were the ICU stay in days and the mortality. To minimise the possibility of bias caused by delays in the transfer of patients to a regular ward due to unavailability of beds, patients were considered ready for discharge and their record was closed when they no longer needed vital-organ support and were receiving at least two-thirds of their caloric intake by the normal enteral route.
Statistical analysis
Nominal and ordinal data are presented as mean ± standard deviation. Means between two groups were compared by Student's two-tailed t-tests or Mann-Whitney U test as appropriate. Binominal data are presented in proportions and compared using Fisher's Exact test or chi-square test as appropriate. All data were processed with SPSS 11.0 for Windows (LEAD Technologies Inc, USA) and NCSS (Hintze J, Number Cruncher Statistical Systems, Kaysville, Utah, USA).
RESULTS
in the MICU, 186 patients were excluded from the brain death, four were less than 18 years old, 33 patients or the closest family member refused consent and from the remaining 101 patients level under 6.1 mmol/l at the admission glycaemic measurement. The remaining 60 patients were enrolled in the study but three patients, two from pulmonary embolism and were lost within 10 hours and the third patient had an acute abdomen and died in the surgical room where she was transported reported an ischaemic colon. From the remaining 57 patients, a total of 6571 blood glucose measurements, 2989 from 26 patients in the SI group and 3582 from 31 patients of the IV group were performed. All enrolled patients had arterial catheters and more than 90% of glycaemia measurements in both groups were measured on measurements in the SI vs. 197 in the IV group, P from mechanical ventilation or had achieved haemodynamic stability for the same period of time.
Demographic data and basal values of patients in both groups were similar and are reported in Table 2 . Study data are reported in Table 3 .
Mean glycaemia represents the arithmetic mean of all individual means of glycaemia for each patient calculated as the sum of glycaemic measurements divided by the number of measurements for that patient. Morning glycaemia is the arithmetic mean of all individual means of morning glycaemia of each patient. Although basal glycaemia at admission were similar in both groups, mean glycaemia were was also noted between both groups for the mean morning glycaemia.
glycaemic levels normalised to time, which is the proportion of time relative to total time of glycaemic both groups. For each patient, the time spent with glycaemia over 6.1 mmol/l is calculated then divided with the total time of glycaemic follow-up. The mean and standard deviation for each group is reported in Table 3 . The same method of calculation was applied for the periods of time spent in glycaemia over mmol/l. There were no complications related to the use of insulin pumps with the exception of hypoglycaemic events detailed below. Neither redness nor cellulitus at the injection site was observed.
The time required to lower the glycaemia from the admission level to the targeted range was calculated for each patient. This parameter is equal to the time measurement. Although the average time required to get in range in the SI group was lower than in the IV group, the difference was not statistically
The results of an independent hyperglycaemic index 9 were found between two groups even when the upper limit of glycaemia was considered at 8.3 mmol/l. The index was calculated for both groups based on the Sixteen hypoglycaemic measurements (0.53%) were recorded in 12 events in four patients in the in 12 patients in the IV group. The rate of hypothe IV group (P <0.01) but if only the total number 0.83 hypoglycaemic events occurred per patient in the SI and IV groups respectively (P=0.16). The hypoglycaemic events concerned 19% of patients in the SI group and 39% of the IV group (P=0.21).
The ICU length of stay was similar in both groups (10.8±11.5 days in the SI group and 10.0±10.6 days in the IV group; P=0.78).
As expected in this study, with a small number of in mortality: 13 patients from the SI group (50%) and 18 patients from the IV group (58%) died in the ICU during the study. 
DISCUSSION
In this study, the subcutaneous route was used for continuous insulin infusion with an insulin pump and glycaemic control was compared to IV insulin infusion. Using the same treatment protocol for both routes, CSII reduced hyperglycaemia as fast as the IV route. Moreover, according to Vogelzang's hyperglycaemic index, CSII maintained glycaemia in the targeted range better than its IV counterpart hypoglycaemic events.
A literature search revealed no publication concerning continuous subcutaneous insulin delivery or the use of an insulin pump in the ICU. Instead, the use of insulin pumps in the ICU setting was not recommended by some authors for practical reasons recommendations 10 .
A sophisticated insulin pump was used in this study in a very simple way. Basal insulin infusion and bolus functions were implemented to match the IV infusion method. As blood glucose levels were the sole determinant for the adjustment of insulin dosing in this study, the scheme used for tight glycaemic control by IV infusion became also applicable for insulin pumps.
The belief that insulin delivered by the IV route should act more rapidly and thus should decrease blood glucose levels faster than the subcutaneous route is now questionable since, in our study, the time required to lower glycaemia to the target range is found to be similar and although not statistically of subcutaneous insulin into the circulation was still effective in patients with septic shock receiving potent vasopressors and in whom tissue perfusion and the microcirculation are known to be altered especially if vasopressor agents are infused 11 . All vasopressor agent and were mechanically ventilated but none of these patients received glucocorticoids. the IV counterpart. As the study was not designed nor powered enough for comparing septic and non-septic patients, the only comparison was the mean time elapsed to bring glycaemia 'in-range' between septic and non-septic patients of each group and although numerically lower values were achieved in non-septic patients, they were not hours for non-septic and septic patients respectively; P non-septic and septic patients respectively; P=0.52).
In this study, the success of each route of insulin infusion to control the glycaemia is evaluated by three parameters; the mean glycaemia, the morning glycaemia and the rate of 'in-range' measurements. Although the number of measurements per patient per day between the two groups was not statistically different, standard deviations were almost half the mean values which report a high variance of the measurements around the mean and, in other words, while some patient's glycaemia were easily controlled and required few measurements, other patients required nearly hourly measurements and closer attention for controlling their glycaemia. To see more clearly with the number of daily glycaemic measurements, the proportion of measurements calculated ( Table 3 ). In other words, these proportions gave a clearer image of the distribution of measurements and the possibility to compare the results of the two groups more thoroughly. The subcutaneous insulin group had better results than the IV group for these parameters. CSII seemed to control the glycaemia better compared to IV insulin infusion under the same decision and treatment scheme used in our MICU. This can partly be explained by the fact that for IV infusions, insulin is in 50 ml, where even slight variations in the concentration of insulin considerably. Moreover, insulin is known to adsorb to the surface of the often share one of the lumens of central catheters where other treatments are streamed with the potential for interference with infusion rates. For subcutaneous infusion, there is no need for extra with 'pure' insulin (3 ml for the pumps used in this study). Only insulin is delivered in a single line. and 32% of the measurements in the IV group were in the targeted range of glycaemia. These low proportions may be explained by the severity of the with the Acute Physiology and Chronic Health Evaluation II scores and daily insulin requirement of patients. Nevertheless, the protocol used for strict glycaemic control allowed keeping 85.7% and 77.7% of glycaemia in the SI and IV groups respectively.
The rates of measurements were not easy to numbers of measurements. Moreover the length of stay of each patient in the ICU was different, Therefore a time-independent hyperglycaemic index introduced by Vogelzang was used in this study 9 . This index is calculated by dividing the sum of areas between the glycaemic curve and the upper limit of glycaemic range by the total length of stay. It has been demonstrated to be a useful measure of glucose control and show a better relationship with outcome 9 . The number of hypoglycaemic measurements was not negligible in this study. Although each hypoglycaemic event had more than one hypoglycaemic measurement, the total number of hypoglycaemic events necessitated a revision in our treatment protocol after reconsideration of study data. In fact, there were 38 hypoglycaemic rate observed in the VISEP and GLUCONTROL trials 12,13 , therefore the treatment protocol in use in our MICU was revisited and bolus doses that patients received according to a glycaemic measurement were reduced by half and control glycaemic measurements were done every 30 minutes until normoglycaemia was achieved.
Glycaemic measurements between 2.2 to SI group. One of the possible explanations for this may be the excessive bolus dosage which would induce hypoglycaemia if it was given by the intravenous route, but slower absorption by the subcutaneous tissue prevented this occurrence. Our knowledge is limited concerning the effect of low glycaemia on the absorption rate of insulin by the subcutaneous tissue except that sympathetic system stimulation by hypoglycaemia may lead to peripheral vasoconstriction. Surprisingly, the sum of daily basal and the sum of bolus doses of insulin administered in the SI Here again it is possible that dilution, adsorption and possibly photosensitivity of insulin solution may explain these differences.
The use of the subcutaneous route brought some advantages with it. First, severely ill patients require the use of multilumen central catheters in order to deliver medications adequately. Use of the subcutaneous route maintains an isolated insulin infusion when a dedicated lumen of a central line may not be available. CSII may reduce the number of manipulations compared to the IV route as insulin syringes need to be replaced as they are emptied or timed out. Each manipulation may increase the risk of catheter-related infections. Finally, from the results of this study, using the same algorithm for both routes, with subcutaneous infusion, it is than and at least as safely as the IV infusion but with less administered insulin.
In this prospective randomised study, regular crystallised human insulin was used in both infusion routes for comparability of action. It is also possible to use insulin analogs which act more rapidly and with a shorter half-life. The advantages of continuous subcutaneous infusion of insulin analogs in critically ill patients are to be determined.
Glucose measurement on arterial blood using bedside glucometers is a frequent procedure in ICU. These glucometers are designed for capillary blood sugar measurements but for practical reasons and for patient comfort, arterial blood samples are used for glycaemic measurements. It is well known that differences exist between whole blood and plasma and in capillary and arterial blood. We chose three publications where Accu-Chek glucometers, reputed to account for differences between whole blood and serum, are involved and where authors compared glucose measurements by this glucose meter and standard laboratory methods on capillary, arterial and venous blood samples and found controversial results . In this study, all patients had arterial catheters and kept them until they required no further frequent blood sampling. After its removal, glycaemia was measured on capillary blood samples but at this point patients were near their transfer to the ward and few measurements per patient were performed by this route. In this way, interchangeability bias was avoided as much as possible.
As the aim of this study was to compare two insulin infusion methods and as the same methods of measurements are used in the same proportions, it is not expected to affect the conclusions.
A major limitation of this study is the small numbers and high exclusion rate. There was lack of homogeneity of patients enrolled and absence of any cost-effectiveness analysis. Another weakness is that the comparison of both routes concerns our algorithm only which may be more suitable for continuous subcutaneous infusion rather than the IV route. It would be interesting to determine the impact of subcutaneous infusion on other environments and treatment schemes. It could also be interesting to determine whether the use of the subcutaneous route for insulin infusion reduces catheter-related infections, ventilator-related pneumonia, renal tubular injuries or improves local as sepsis.
CONCLUSION
Despite the small number of patients enrolled in this prospective randomised study, with our IV insulin infusion for tight glycaemic control in critically ill patients in the MICU. The use of the subcutaneous route has some practical advantages clinical advantages such as reduction in catheterrelated infections or reduced mechanical ventilation days. If developed, insulin pumps with basic functions could also be used in ICUs for subcutaneous infusions but cost-effectiveness is yet to be proved.
